TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03960996

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dacryocystorinostomy
Description: Dacryocystorinostomy is a surgical procedure indicated in patients with lacrimal duct obstruction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dacryocystorinostomy
Description: Dacryocystorinostomy is a surgical procedure indicated in patients with lacrimal duct obstruction.
Study: NCT04522544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 300 mg Tremelimumab C1D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 300 mg Tremelimumab C1D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg Durvalumab C1D1 + Q4W (max. 13 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg Durvalumab C1D1 + Q4W (max. 13 cycles)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Y-90 SIRT
Description: Locoregional therapy will be performed as a standard-of-care procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DEB-TACE
Description: Locoregional therapy will be performed as a standard-of-care procedure
Study: NCT02695563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin
Study: NCT01315639

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: biomarkers, MRI and CSF
Description: MRI at Day 0 and month 24 (or conversion) Biomarkers at Day 0 et month 24 (or conversion) CSF at D0
Study: NCT04863469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: B-POC high load intervention
Description: aerobic exercise \[heartrate range (HRR) 70-75% of max HR, on treadmill\] and a computerized high-load task for 45 minutes, 3 times per week, for 6 weeks

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: B-POC low load intervention
Description: aerobic exercise \[heartrate range (HRR) 70-75% of max HR, on treadmill\] and a computerized low-load task for 45 minutes, 3 times per week, for 6 weeks
Study: NCT00487656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART-123
Description: 6mg/ml ampule solution for injection @ .01mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 6 mg/ml ampule solution for injection at .01mg/kg
Study: NCT01111799

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial biopsy
Description: two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial biopsy
Description: two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: natural cycle + IUI + endometrial biopsy
Description: two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
Study: NCT03578783

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSD502
Description: For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing.
Study: NCT00045617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody 11D10 anti-idiotype vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody GD2 anti-idiotype vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02335788

Intervention type: DEVICE
Group type: OTHER
Intervention: The EMBA Peripheral Embolization Device
Description: arterial and venous embolization in the peripheral vasculature
Study: NCT01039519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Description: Ganetespib 200 mg/m\^2 during an approximately 1-hour infusion once weekly for three consecutive weeks followed by a treatment-free week. Participants who demonstrate acceptable tolerability and objective clinical benefit (defined by at least stable disease or objective response per RECIST) can continue to receive ganetespib until disease progression or appearance of unacceptable toxicity.
Study: NCT01229267

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212
Description: V212 viral antigen for HZ. Participants will receive consistency Lot 1, 2, or 3 or the High Antigen Lot.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212
Description: V212 viral antigen for HZ. Participants will receive consistency Lot 1, 2, or 3 or the High Antigen Lot.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212
Description: V212 viral antigen for HZ. Participants will receive consistency Lot 1, 2, or 3 or the High Antigen Lot.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212
Description: V212 viral antigen for HZ. Participants will receive consistency Lot 1, 2, or 3 or the High Antigen Lot.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Vaccine stabilizer for V212 with no virus antigen
Study: NCT03329638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-127 Ophthalmic Solution low dose
Description: Low dose of DE-127 Ophthalmic Solution dosed once daily for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-127 Ophthalmic Solution medium dose
Description: Medium dose of DE-127 Ophthalmic Solution dosed once daily for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-127 Ophthalmic Solution high dose
Description: High dose of DE-127 Ophthalmic Solution dosed once daily for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution
Description: Placebo Ophthalmic Solution dosed once daily for 12 months
Study: NCT03678220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LapAR
Description: LapAR system will be used for guidance during laparoscopic hepatectomy and laparoscopic liver thermal ablation
Study: NCT01718405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive function after exercise test
Description: The individual subjects will participate in 3 sessions of either aerobic exercise, resistance exercise or rest, in a random order. Before and after each session, the subject will take computerized cognitive tests.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood sample analysis
Description: In the first evaluation session blood samples will be taken from each subject and will be analysed for genetic polymorphism.
Study: NCT02013271

Intervention type: DEVICE
Intervention: Lutonix Paclitaxel Drug Coated Balloon (DCB)
Description: Patients exposed to the DCB as part of their routine care.
Study: NCT00184301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inpatient treatment
Description: inpatient treatment during 1 year

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: outpatient treatment
Description: intensive outpatient treatment consisting of two-weekly group sessions during 1 year
Study: NCT04441918

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: JS016 (anti-SARS-CoV-2 monoclonal antibody)
Description: JS016 (anti-SARS-CoV-2 monoclonal antibody)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: JS016 (anti-SARS-CoV-2 monoclonal antibody)
Description: JS016 (anti-SARS-CoV-2 monoclonal antibody)
Study: NCT01956929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1000mg daily for one week, then 2000 mg daily for the second week. 4 week washout period, then crossover to placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for 2 weeks, then 4 weeks of washout period, then crossover to metformin.
Study: NCT03543917

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Perfusion with New Combination Medication
Description: Intravenous administration of Actovegin, vitamins B1, B6, B12, C, oxytocin/dexamethasone, calcium gluconate, etc in 250 ml normal saline administered during approximately 2 hours
Study: NCT03652285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal stent implantation
Description: An upper endoscopy will be performed with the use of fluoroscopy. Depending on the size of the stricture a dilation can be performed prior to the stent deployment. Otherwise, the stent will be deployed over a guidewire, under fluoroscopy.~After, the gastroscopy will go through the esophagus to check for the stent deployment, or any complications.~An injection of contrast agent will be done to be sure of the correct positioning and that no complications was happened.~The patient will be kept overnight, with liquid food for 3 days and under PPI until one month after the stent placement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent removal
Description: Six months after implantation, the removal of the stent will be performed. Patient will undergo a first endoscopy under general anesthesia for the placement of a FCSEMS. Then, depending on the importance of the hyperplasia, removal of both stents, under general anesthesia, will be done after 7 to 10 days.
Study: NCT00004554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone (Revia)
Description: 100mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone (Revia)
Description: 100mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline (Zoloft)
Description: 200mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline (Zoloft)
Description: 200mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04259619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy
Description: The low-level laser emits monochromatic, coherent, bundled laser light. In each therapy a energy dose of 2-4 Joul (J) / centimeter (cm)\^2 is applied over a duration of about 30 seconds using level 1 (20 percent of maximum output) of the 350 milliwatt (mW) device.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Therapy
Description: The intervention is conducted identically to the low-level laser therapy but the placebo laser that is used emits only red light that is polychromatic, leading to a reduction in energy being emitted and therewith to no or a smaller effect.
Study: NCT02025413

Intervention type: DEVICE
Group type: OTHER
Intervention: Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)

Intervention type: DEVICE
Group type: OTHER
Intervention: Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
Study: NCT00254384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04294680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: see opiate sparing description
Study: NCT00985361

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2000 international units daily
Description: Vitamin D3 2000 international unit tablets once daily for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C 500mg daily
Description: Vitamin C 500mg tablets once daily for 3 months
Study: NCT03669497

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypo fractionated whole breast radiotherapy
Description: Hypo fractionated radiotherapy to the whole breast and SCF to a dose of 26 GY in 5 fractions with simultaneous integrated boost in advanced incurable breast cancer
Study: NCT01926262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specific Strength Training
Description: Specific Strength Training for the Neck and Shoulder Muscles
Study: NCT00673738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: * Cetuximab dose: based on patient's actual weight. Loading phase dose of cetuximab is 400 mg/m2 IV administered over 120 minutes, on day 1 followed by; Concurrent phase, weekly infusion dose at 250 mg/m2 IV over 60 minutes, on days 8, 15, 22, 29, 36, 43, 50.~* Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week complete blood counts (CBCs), differentials, and blood urea nitrogen (BUN) plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conformal Thoracic Radiotherapy (CTRT)
Description: * Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week CBCs, differentials, and BUN plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted.~* Radiation therapy will begin on day 8 (with window of ± 3 days). Adequate hematologic profile (ANC \>1,000 and platelets \>75,000) required. Patient may be delayed for a max. of 2 weeks. If \> 2 week delay occurs, patient will come off study.
Study: NCT04643613

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protison cancer nutritional formula (PCNF)
Description: PCNF (237 mL/Pack) for 5-6 times/day via bolus NG tube feeding for 12 weeks
Study: NCT00404222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen Extended-Release
Description: 2 tablets x 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone/Acetaminophen Immediate Release (NORCO®)
Description: 1 tablet q 4 hours x 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: q 4 hours x 3
Study: NCT03035357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: 16 mg/kg by vein once weekly for a total of 4 doses.
Study: NCT02185495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Observer nodule detection
Description: Radiologists will detect the nodules.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-aided nodule detection
Description: Computed-aided detection (CAD) software will be used to detect the nodules.
Study: NCT02324348

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deferred coronary stenting
Description: Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In deferred stenting group, second stage procedure (stent implantation) will be done at 5 to 7 days after TIMI Ⅲ flow has achieved.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Immediate coronary stenting
Description: Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In immediate stenting group, stenting will be done immediate after achieving TIMI III flow during initial procedure.
Study: NCT03590041

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized SMA
Description: Patients receiving the Standardized SMA intervention will be part of group visits that cover a modified TTIM 6-session curriculum, delivered only by health educators. The Standardized SMA approach will be uniformly administered at each practice. Topics will be covered in a predetermined order and patients will not have a say in terms of what content they wish to cover. Patients receive the Standardized SMA approach if their practice is randomly assigned to the Standardized SMA arm. Practices are cluster-randomized to deliver a standardized or patient-driven group visit model.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient-driven SMA
Description: Patients receiving the Patient-driven SMA intervention will be part of group visits that cover a modified TTIM 6-session curriculum, but patients are in control of time spent and order of the topics. The Patient-driven SMA will be delivered by a multidisciplinary team consisting of a Health Educator, medical provider, Behavioral Health Professional, and a diabetes peer mentor. Patient-driven SMAs may be delivered differently at each practice, as patients choose the topics that are most important to spend the most time on. All topics will be covered, but the order and time spent is up to the group. Patients receive the Patient-driven SMA approach if their practice is randomly assigned to that arm. Practices are cluster-randomized to deliver a standardized or patient-driven SMA model.
Study: NCT04396639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moroctocog-alfa (AF-CC)
Description: Moroctocog-alfa (AF-CC) is indicated for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).
Study: NCT04285970

Intervention type: OTHER
Intervention: cycle detection
Description: 6-minute test on a treadmill at pedestrian speed (5km/h) with 2 instruments (dynamometric wheel and inertial centre) on a standardised wheelchair

Intervention type: OTHER
Intervention: detection of effort intensity
Description: 6-minute test on an urban course with 2 instruments (dynamometric wheel and inertial units) on a wheelchair
Study: NCT02790892

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Art therapy - pre and post test measures
Description: 12 weeks of 90 minutes of art therapy with pre and post test measures to determine changes in social support and levels of diabetes distress
Study: NCT00087867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCIO-469
Description: two 30-mg capsules three times daily

Intervention type: DRUG
Group type: OTHER
Intervention: SCIO-469 and bortezomib
Description: In addition to SCIO-469, patients with disease progression will receive bortesomib 1.0 mg/m2 intravenously as a bolus injection on Days 1, 4, 8, and 11 of a 21-day cycle, followed by a 10-day rest period
Study: NCT04516889

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Doubled sutured SFIOL
Description: Recruited subjects would undergo implantation of SFIOL with the modified technique under either local or general anesthesia. The surgeon would mark the sclerotomies as per routine sutured SFIOL at 2mm behind the nasal and temporal limbus, followed by passage of 2 pairs of prolene sutures. The intraocular lens with islets would be implanted into the posterior chamber and sutured to the sclera as per single suture SFIOL.
Study: NCT02740023

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid (Phonak Audéo V90-13)
Description: Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90-13 will be fitted to the participants individual Hearing loss.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid (Successor of Phonak Audéo V90-13)
Description: The successor of Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90-13 will be fitted to the participants individual Hearing loss.
Study: NCT04277338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECT
Description: One single injection of 99mTc-HE3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECT
Description: One single injection of 99mTc-HE3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECT
Description: One single injection of 99mTc-HE3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
Study: NCT01082068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL147 (SAR245408)
Description: given orally once daily as tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL765 (SAR245409)
Description: given orally twice daily as capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole (Femara)
Description: given orally once daily as tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole (Femara)
Description: given orally once daily as tablets
Study: NCT00885170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: Odanacatib 50 mg tablets once weekly for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to odanacatib 50 mg tablets once weekly for 24 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3, two 2800 IU tablets, taken once weekly for 24 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3, two 2800 IU tablets, taken once weekly for 24 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Participants will receive calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium
Description: Participants will receive calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
Study: NCT02282098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 0.6mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Colchicine